Abstract
Cancer-immune (CI) equilibrium constitutes an important component of the cancer immunoediting theory. It is defined as a period during which our immune system and cancer live in harmony in the body. The immune system, though not able to completely eliminate the cancer, doesn’t allow it to progress or metastasize further. Mechanisms of this phase are poorly understood because this phase is difficult to identify even by the most modern detection methods. Till now, the work done on the equilibrium phase of cancer, suggests promising improvements in cancer therapy if the disease could be withheld in this phase. However, there are many queries which remain to be addressed about this interesting yet unresolved phase of cancer immunity.
Similar content being viewed by others
References
Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360
Teng MWL, Swann JB, Koebel MC, Schreiber RD, Smyth JM (2008) Immune-mediated dormancy: an equilibrium with cancer. J Leukocyte Biol 84:988–993
Kauffman HM, McBride MA, Delmonico FL (2000) First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 70:1747–1751
Myron KH, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM (2002) Transplant tumor registry: donor related malignancies. Transplantation 74:358–362
MacKie MR, Reid R, Junor B (2003) Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Eng J Med 348:567–568
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Eng J Med 346:564–569
Dhodapkar MV, Krasovsky J, Osman K, Geller MD (2003) Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 198:1753–1757
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907
Naumov GN, MacDonald IC, Chambers AF, Groom AC (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11:271–276
Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153
Ehrlich P (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5(Part 1):273–290
Kim R, Emi M, Tanabe K (2008) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14
Bernardone IS (2008) Role of NK cells and adaptive immunity in “immunoediting”: recent developments. Immunologia 27:141–146
Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81
Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 348:203–213
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964
Mahnke YD, Schwendemann J, Beckhove P, Schirrmacher V (2005) Maintenance of long term tumor-specific T-cell memory by residual dormant tumor cells. Immunology 115:325–336
Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW et al (1999) Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN—in establishing and maintaining the tumor-dormant state. J Immunol 162:2842–2849
Hermelink MN, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K et al (2008) Tnfr1 signaling and IFN-G signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507–518
Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848
Baguley BC (2006) Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent patents on anti-cancer drug discovery 1:121–127
Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R et al (2009) EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 113:3494–3502
Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H et al (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88:577–583
Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M et al (2003) Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20:445–451
Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J et al (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23–28
Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM et al (2008) Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 68:1563–1571
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M et al (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656–660
Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumor dormancy. APMIS 116:754–770
Felsher DW (2006) Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 5:1808–1811
Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153
Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H et al (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779–791
Hakansson L (2009) The capacity of the immune system to control cancer. Eur J Cancer 45:2068–2070
Vence LA, Palucka K, Fay JW, Ito T, Liu Y, Banchereau J et al (2007) Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 104:20884–20889
Cruz-Merino LDL, Grande-Pulido E, Albero-Tamarit A, Villenaa MEC (2008) Cancer and immune response: old and new evidence for future challenges. The Oncologist 13:000–000
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65(22):10139–10144
Frey AB (2006) Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 116:2587–2590
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Eng J Med 285:1182–1186
Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846
Beitsch JF, Leitch PD, Hoover M, Euhus S, Haley D, Morrison B et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Eng J Med 353:793–802
Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Bou-Ghalia A, Cook M et al (1996) A comparison of immunohistochemistry, two‑color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 5:57–62
Naume B, Borgen E, Tossvik S, Pavlak N, Oates D, Nesland JM (2004) Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 6:244–252
Fodstad O, Hoifodt HK, Rye PD, Trones GE, Beiske K (1996) New immunobead techniques for sensitive detection of malignant cells in blood and bone marrow. Proc Am Assoc Cancer Res 37:214
Griwatz C, Brandt B, Assmann G, Zanker KS (1995) An immunological enrichment method for epithelial cells from peripheral blood. J Immunol Methods 183:251–265
Arbab AS, Liu W, Frank JA (2006) Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices 3:427–439
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456
Harper J, Naumov GN, Exarhopoulos A, Bender E, Louis G, Folkman J, et al (2006) Predicting the switch to the angiogenic phenotype in a human tumor model. In: Proceedings of the American Association for Cancer Research 837
Klement G, Kikuchi L, Kieran M, Almog N, Yip TT, Folkman J (2004) Early tumor detection using platelet uptake of angiogenesis regulators. Blood 104:239a
Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi et al (2008) Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111:1201–1207
Felsher DW (2006) Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 5:1808–1811
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456
Demicheli R (2001) Tumor dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11:297–306
Barrett AJ, Savani BN (2009) Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 23:53–58
Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117:1195–1203
Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339
Favaro E, Amadori A, Indraccolo S (2008) Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. APMIS 116:648–659
Clemente CG, Mihm JMC, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310
Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932–3936
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 348:203–213
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417
Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14(2):425–431
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G et al (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957–2964
Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S (2008) Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica 93:193–200
Conflict of Interest
The author(s) declare that they have no conflict of interest
Disclosure of Funding
No funding has been received from any agency for this work
Authors’ Contributions
AB conceptualized, designed and drafted the manuscript. YK has drafted the manuscript and has revised it critically for important intellectual content. Both the authors have read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhatia, A., Kumar, Y. Cancer-Immune Equilibrium: Questions Unanswered. Cancer Microenvironment 4, 209–217 (2011). https://doi.org/10.1007/s12307-011-0065-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12307-011-0065-8